TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04005508

Intervention type: DIAGNOSTIC_TEST
Intervention: Overnight sleep study
Description: The patients will undergo an overnight sleep study using Watch-PAT sleep study device

Intervention type: DIAGNOSTIC_TEST
Intervention: Overnight sleep study
Description: The patients will undergo an overnight sleep study using Watch-PAT sleep study device
Study: NCT02194738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT00052299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone hydrochloride
Study: NCT00901212

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device programming
Description: 6-month period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device programming
Description: 6-month period
Study: NCT00644852

Intervention type: OTHER
Intervention: Retrospective chart review study
Description: Retrospective study chart review long acting risperidone
Study: NCT04127630

Intervention type: PROCEDURE
Intervention: mobilization of the larynx
Description: we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
Study: NCT00299286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lapatinib-Placebo
Description: In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose.
Study: NCT01090752

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Study: NCT05174195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel 0.075 milligram
Description: Inserted after 3 months use of DESOGESTREL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Implanon NXT® subdermal implant
Description: Inserted immediately

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Implanon NXT® subdermal implant
Description: Inserted immediately
Study: NCT01635283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor lysate-pulsed autologous dendritic cell vaccine
Description: Given ID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03115268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support groups delivered in EVA Park
Description: Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social support groups delivered in EVA Park
Description: Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
Study: NCT04423185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib 110 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib 150 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
Study: NCT00950391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
Study: NCT04309305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EksoGT™, Ekso Bionics, Berkley, CA, USA
Description: The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard gait therapy provided by licensed physical therapists post stroke.

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Testing Only
Study: NCT03729037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR self-training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR self-training
Study: NCT02083848

Intervention type: OTHER
Group type: OTHER
Intervention: 7T MRI
Description: Ultra high field magnetic resonance imaging
Study: NCT03350256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Description: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
Study: NCT01478685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2
Study: NCT03354312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 1% Gel
Description: Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 1% Gel
Description: Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine hydrochloride/epinephrine (adrenaline) hydrochloride
Description: Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine hydrochloride/epinephrine (adrenaline) hydrochloride
Description: Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
Study: NCT00914446

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hepatic biopsies
Description: hepatic biopsies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hepatic biopsies
Description: hepatic biopsies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hepatic biopsies
Description: hepatic biopsies
Study: NCT00571870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrorelix acetate
Description: The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetrorelix acetate
Description: The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
Study: NCT05587062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept (CinnaGen Co, Iran)
Description: Aflibercept (CinnaGen Co, Iran) by intravitreal injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept (Regeneron, USA)
Description: Aflibercept (Regeneron, USA) by intravitreal injection
Study: NCT02185573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bulk fill
Description: This is one of the composite restoration application techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SonicFill
Description: This is the recent intervention under evaluation
Study: NCT04278768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
Study: NCT02194738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study: NCT02709785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse
Description: Subjects use chlorhexidine mouth rinse for six weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rinse
Description: Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
Study: NCT02194738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue
Study: NCT04423185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib 160/80 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib 160/80 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200/300 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200/300 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
Study: NCT02194738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT04423185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib 240 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib 240 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab 100MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
Study: NCT02194738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04423185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab 100MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
Study: NCT02194738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT04423185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1680 MG
Description: Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1680 MG
Description: Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
Study: NCT00010374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuRx DPS
Description: Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.
Study: NCT04278768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
Study: NCT02194738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01679717

Intervention type: OTHER
Group type: OTHER
Intervention: Early mobilisation after CMC1-surgery
Description: Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilisation after CMC1-surgery
Description: Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
Study: NCT00905710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Description: Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine